Find Oncology Drugs in Phase I/II Clinical Development in SWITZERLAND

Lead Product(s): Debio 1143,Cisplatin

Therapeutic Area: Oncology

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 27, 2020

Details:

The FDA decision was based on the compelling magnitude of the clinically phase II findings in combination with chemo-radiotherapy presented in September 2019 at the ESMO congress.

Lead Product(s): Derazantinib,Atezolizumab

Therapeutic Area: Oncology

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 22, 2020

Details:

Both companies will conduct a study which will assess the efficacy and safety of derazantinib as mono- and combination therapy in the second-line setting.